بدائل البحث:
ng decrease » _ decrease (توسيع البحث), we decrease (توسيع البحث), gy decreased (توسيع البحث)
nn decrease » _ decrease (توسيع البحث), mean decrease (توسيع البحث), gy decreased (توسيع البحث)
c decrease » c decreased (توسيع البحث), _ decrease (توسيع البحث), rc decreased (توسيع البحث)
a decrease » _ decrease (توسيع البحث), _ decreased (توسيع البحث), _ decreases (توسيع البحث)
50 c » 5 c (توسيع البحث), 50 μ (توسيع البحث), 50 _ (توسيع البحث)
ng decrease » _ decrease (توسيع البحث), we decrease (توسيع البحث), gy decreased (توسيع البحث)
nn decrease » _ decrease (توسيع البحث), mean decrease (توسيع البحث), gy decreased (توسيع البحث)
c decrease » c decreased (توسيع البحث), _ decrease (توسيع البحث), rc decreased (توسيع البحث)
a decrease » _ decrease (توسيع البحث), _ decreased (توسيع البحث), _ decreases (توسيع البحث)
50 c » 5 c (توسيع البحث), 50 μ (توسيع البحث), 50 _ (توسيع البحث)
-
21
-
22
-
23
-
24
-
25
mGluR5 receptor decreased glycinergic currents.
منشور في 2019"…(<b>E</b>) The inhibitory effect of CHPG on GlyR-IPSCs was not blocked by intracellularly loaded GDP-β-S (62.3 ± 6.4% of baseline at 15–20 min post-CHPG, <i>t</i>[6] = 2.782, <i>p</i> = 0.032), chelerythrine (60.9 ± 11.3% of baseline at 15–20 min post-CHPG, <i>t</i>[6] = 2.705, <i>p</i> = 0.035), or Ro-32-0432 (69.9 ± 3.2% of baseline at 15–20 min post-CHPG, <i>t</i>[5] = 8.495, <i>p</i> < 0.001). (<b>F</b>) Postsynaptic loading of U-0126 or PD98059 prevented CHPG from decreasing glycinergic responses (U-0126, 107.6 ± 10.4% of baseline at 15–20 min post-CHPG, <i>t</i>[8] = 0.997, <i>p</i> = 0.348; PD98059, 93.1 ± 5.0% of baseline at 15–20 min post-CHPG, <i>t</i>[5] = 0.883, <i>p</i> = 0.418). …"
-
26
-
27
Development of a CRISPR/Cas-Based Detection Platform for Tracking Decreased Susceptibility to Cephalosporins in Neisseria gonorrheae
منشور في 2025"…MIRCA enables multiplex detection of <i>Ng</i> and single-nucleotide polymorphisms in resistance-associated genes within 40 min, with high specificity and sensitivity (10–20 copies/reaction). …"
-
28
-
29
-
30
-
31
-
32
-
33
-
34
6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations
منشور في 2025"…Here, we evaluated the aging and neurodegenerative effects of F-53B using the C. elegans model. After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …"
-
35
6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations
منشور في 2025"…Here, we evaluated the aging and neurodegenerative effects of F-53B using the C. elegans model. After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …"
-
36
6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations
منشور في 2025"…Here, we evaluated the aging and neurodegenerative effects of F-53B using the C. elegans model. After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …"
-
37
6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations
منشور في 2025"…Here, we evaluated the aging and neurodegenerative effects of F-53B using the C. elegans model. After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …"
-
38
-
39
-
40